Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update
by Doug Wharley · The Cerbat GemNeuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 21,719 shares, a drop of 66.7% from the November 30th total of 65,284 shares. Based on an average daily volume of 101,515 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.4% of the company’s stock are short sold. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 101,515 shares, the days-to-cover ratio is presently 0.2 days.
Neuphoria Therapeutics Stock Down 1.8%
Shares of NASDAQ:NEUP traded down $0.07 during trading on Friday, reaching $3.72. The stock had a trading volume of 24,284 shares, compared to its average volume of 562,392. Neuphoria Therapeutics has a 52 week low of $2.90 and a 52 week high of $21.40. The firm has a market capitalization of $20.00 million, a price-to-earnings ratio of -0.76 and a beta of 0.51. The stock has a fifty day simple moving average of $4.82 and a two-hundred day simple moving average of $8.12.
Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($4.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, analysts forecast that Neuphoria Therapeutics will post -1.56 EPS for the current year.
Insider Buying and Selling
In related news, major shareholder Lynx1 Capital Management Lp acquired 639,110 shares of the company’s stock in a transaction on Tuesday, October 21st. The shares were purchased at an average price of $5.14 per share, for a total transaction of $3,285,025.40. Following the purchase, the insider owned 875,328 shares in the company, valued at $4,499,185.92. This represents a 270.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company’s stock.
Hedge Funds Weigh In On Neuphoria Therapeutics
An institutional investor recently bought a new position in Neuphoria Therapeutics stock. Persistent Asset Partners Ltd bought a new stake in Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,908 shares of the company’s stock, valued at approximately $58,000. Persistent Asset Partners Ltd owned about 0.21% of Neuphoria Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 15.90% of the company’s stock.
Analyst Ratings Changes
A number of research firms have recently weighed in on NEUP. Weiss Ratings downgraded shares of Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, October 8th. HC Wainwright lowered their target price on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, December 5th. Zacks Research downgraded Neuphoria Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, December 8th. Maxim Group boosted their price target on Neuphoria Therapeutics from $18.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Finally, Wall Street Zen downgraded Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $21.00.
Check Out Our Latest Stock Report on NEUP
Neuphoria Therapeutics Company Profile
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.